摘要
目的探讨TFPI-2mRNA在卵巢癌组织中的表达以及与卵巢癌临床病理特征的关系。方法以β-actin基因为参照,应用逆转录聚合酶链反应(RT-PCR)技术,检测40例卵巢癌患者的肿瘤中心处癌组织、肿瘤边缘癌组织及癌旁正常卵巢组织中TFPI-2的表达。应用条带密度分析软件TotalLabv2.01,定量分析RT-PCR产物电泳带密度。结果正常腺体组织中TFPI-2mRNA的表达水平为0.44±0.10,明显高于肿瘤中心处癌组织(P<0.05);中心处癌组织中TFPI-2mRNA的表达水平为0.60±0.11,明显高于肿瘤边缘处癌组织(P<0.05)。TFPI-2mRNA表达与淋巴转移有关(t=2.71,P<0.05),而与患者年龄、癌肿的大小、临床病理分期和病理类型无关(P>0.05)。结论正常卵巢组织中TFPI-2mRNA的表达水平明显高于卵巢癌组织,且肿瘤边缘处癌组织表达最低,其表达下降与卵巢癌的发生、发展及淋巴转移有关。
Objective To study tissue factor pathway inhibitor-2 （TFPI-2） gene expression in ovarian cancer and its clinicopathologic significance. Methods In 40 patients with ovarian cancers, TFPI-2 mRNA was detected at center and periphery of tumor and at nearby normal tissue by RT-PCR. Results The difference in TFPI-2 mRNA expressions between normal ovarian tissue and cancer was significant （ t = 12.08, P 〈 0.05）, and the expression was significantly higher at the tumor center than that at the tumor periphery （ t = 7.52, P 〈 0.05）. TFPI-2 lower-expression was related to lymph node metastases （ t = 2.71, P 〈 0.05）, but not to age, tu- mor size, pathologic grade or pathologic type （ P 〉 0.05）. Conclusion TFPI-2 lower-expression may play a crucial role in the progression of ovarian cancer and lymph node metastasis.
出处
《实用肿瘤学杂志》
CAS
2007年第4期325-327,329,共4页
Practical Oncology Journal
